| IMMUNITYBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US45256X1037 / A2QQ2E |
| 26CA (Frankfurt) / IBRX (NASDAQ) |
| FRA:26CA, ETR:26CA, 26CA:GR, NASDAQ:IBRX |
| - |
| https://immunitybio.com/ |
|
ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead pr..
>Volltext.. |
| 6359.37 Mio. EUR |
| 6872.32 Mio. EUR |
| 98.14 Mio. EUR |
| -208.35 Mio. EUR |
| -304.42 Mio. EUR |
| -0.34 EUR |
| 731.75 Mio. EUR |
| 76.53 Mio. EUR |
| -264.17 Mio. EUR |
| 3.93 |
| 577.2% |
| 25.11% |
| - |
| - |
| - |
| - |
| IMMUNITYBIO |
| 05.04.26 |
|